^
Association details:
| Biomarker: | STAT3 expression |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | BP1003 (STAT3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
3285 / 2 - Targeting STAT3 with novel liposome-incorporated antisense oligonucleotide technology enhances the efficacy of paclitaxel (taxol) and 5-fluorouracil (5-FU) in breast and ovarian cancer cells
Published date:
03/09/2022
Excerpt:
Treatment of BT549, SK-Br-3 and SK-Ov-3 cells with 250 μg/ml of BP1003 resulted in a 30%-50% decrease in STAT3 expression. Cell viability decreased by 20-35% with 200 μg/ml of BP1003 and by 45-60% in combination with taxol or 5-FU. BP1003 in combination with taxol also decreased the colony formation potential of BT549 cells by 20%. Migration of BT549 cells was reduced by 30% with 200 μg/ml BP1003 alone and by 50% in combination with taxol.BP1003 efficiently reduces STAT3 expression and enhances the sensitivity of breast and ovarian cancer cells to taxol and 5-FU.
Secondary therapy:
paclitaxel + 5-fluorouracil
